Alkem Laboratories Limited has disclosed receiving a significant GST demand order from West Bengal tax authorities, totaling ₹9.72 crores for the financial year 2021-22. The pharmaceutical company made this disclosure on December 30, 2025, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Order Details

The demand order was issued by the Deputy Commissioner, Large Taxpayer Unit, Corporate Division, West Bengal, and was received by the company on December 29, 2025. The order pertains to the company's West Bengal GSTIN for FY2021-22.

The demand has been raised under the applicable provisions of the Integrated Goods and Services Tax (IGST) Act, 2017, Central Goods and Services Tax (CGST) Act, 2017, and State Goods and Services Tax (SGST) Act, 2017.

Nature of Alleged Violations

The GST demand order primarily alleges two main issues:

• Reverse Charge Mechanism: Alleged non-compliance with GST levy requirements under the reverse charge mechanism
• Input Tax Credit: Alleged excess availment of Input Tax Credit beyond permissible limits

The company has clearly stated that it does not agree with the allegations made in the demand order and intends to challenge the same through appropriate legal remedies.

Company's Response and Next Steps

Alkem Laboratories has indicated that it is in the process of taking appropriate action against the order, including filing an appeal with the relevant appellate authority. The company's response demonstrates its intention to contest the demand through established legal channels available under the GST framework.

Financial Impact Assessment

According to the company's disclosure, there is no material impact expected on the financial, operational, or other activities of the organization from this GST order. This assessment suggests that the company views the demand as contestable and expects to successfully challenge it through the appellate process.

The disclosure has been made available on the company's official website at www.alkemlabs.com , ensuring transparency and compliance with regulatory requirements for investor information.

Alkem Laboratories Limited has received a GST demand order from statutory authorities totaling ₹56.71 crores for the financial year 2018-19. The pharmaceutical company disclosed this development on December 30, 2025, in compliance with SEBI LODR Regulations.

GST Demand Order Details

The order was issued by the Assistant Commissioner, Ward 203, Zone 11, Delhi, and received by the company on December 29, 2025. The demand pertains to the company's Delhi GSTIN for FY2018-19.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit under the applicable provisions of the Central Goods and Services Tax (CGST) Act, 2017 and State Goods and Services Tax (SGST) Act, 2017. The company has clearly stated its disagreement with the allegations made in the demand order.

Company's Response and Next Steps

Alkem Laboratories has indicated that it is in the process of taking appropriate action against the order, including filing an appeal. The company maintains that it does not agree with the demand order and will contest the same through proper legal channels.

Impact Assessment

According to the company's disclosure, there is no material impact on the financial, operational, or other activities of Alkem Laboratories due to this GST demand order. The company has made this information available on its website at www.alkemlabs.com for stakeholder reference.

The disclosure was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer, ensuring proper compliance with regulatory requirements under SEBI LODR Regulations.